Stemline Therapeutics Sets New 12-Month Low at $10.53 (STML)
Shares of Stemline Therapeutics (NASDAQ:STML) hit a new 52-week low during trading on Thursday , ARN reports. The stock traded as low as $10.53 and last traded at $10.92, with a volume of 117,263 shares traded. The stock had previously closed at $11.10.
The stock’s 50-day moving average is $12.22 and its 200-day moving average is $17.23. The company’s market cap is $142.3 million.
Stemline Therapeutics (NASDAQ:STML) last released its earnings data on Thursday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.24. On average, analysts predict that Stemline Therapeutics will post $-2.43 earnings per share for the current fiscal year.
Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.